Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Next Previous
Trial Profile

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Decompensated heart failure; Ischaemic stroke; Myocardial infarction; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMMANDER-HF
  • Sponsors Bayer; Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 01 Jan 2022 Results published in the Clinical Research in Cardiology
  • 03 Aug 2021 Results of systematic review and meta-analysis fom COMMANDER HF, ATLAS ACS 2-TIMI 51 and COMPASS; evaluating efficacy and safety of rivaroxaban in patients with coronary artery disease, heart failure and sinus rhythm, published in the European Journal of Clinical Pharmacology
  • 17 May 2021 Results of Meta-Analysis from Atlas-ACS-2 TIMI-51, COMMANDER HF, COMPASS and VOYAGER PAD; assessing whether low-dose Rivaroxaban is associated with reduction in ischemic outcomes but with increased bleeding, presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top